Autoinflammatory Diseases Clinical Trial
Official title:
Epidemiology and Clinico-genetic Correlations of Auto-inflammatory Diseases
Systemic autoinflammatory diseases (SAIDs) are inflammatory conditions caused by a defect of the innate immune system. Most are hereditary, but little is known on recent entities. The investigators aim to (1) establish correlations between the main mutations and symptoms presented by patients (genotype-phenotype correlation), and (2) describe the most recently described clinical, genetic, and demographic characteristics of SAIDs.
Background SAIDs are a heterogeneous group of diseases linked to a deregulation of the innate
immune system. They are characterized by systemic or organ inflammatory attacks. In the
absence of accurate diagnosis and adequate treatment, evolution can be lethal. Most SAIDs are
hereditary, and the diagnosis is based on genetic analysis because the clinical features
overlap. The investigators have been among the first in France to routinely develop Next
Generation Sequencing (NGS), which allows a simultaneous and exhaustive analysis of a
constantly evolving panel of now more than 60 genes involved in SAIDs. While there are
epidemiological studies on the first described MAIs, nothing has been done regarding the
newest clinical entities.
Objectives The investigators want to study and value the data the investigators have
collected on the most recent SAIDs (500 patients) Main objective: Establish correlations
between the main mutations and symptoms presented by patients (genotype-phenotype
correlation).
Secondary objectives: Descriptive epidemiology study: Describe the most recently described
clinical, genetic, and demographic characteristics of SAIDs.
Methodology The investigators have over the last 20 years set up a database that continues to
evolve. These data are collected prospectively from patients (N> 7000) with SAID refered to
our laboratory for genetic analysis. This database contains invaluable demographic, clinical
and genetic data, carefully collected for each patient, on a standard file of analysis
request made with clinicians from the reference center for auto-inflammatory diseases and
amyloidosis (CeRéMAIA). The collection of consent is systematic (declared collection).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Recruiting |
NCT06417502 -
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
|